FDA Clears Hologic’s Automated Platform for Cervical Cancer Cervista HPV Assay

FDA approved Hologic’s Cervista HTA (high-throughput automation) system for use with the firm’s already cleared Cervista human papillomavirus (HPV) HR test. The assay uses Hologic’s Invader technology to detect 14 high-risk HPV types associated with cervical cancer and precancerous lesions.
Genetic Engineering & Biotechnology News